Volume 38, Issue 4 pp. 329-338
Research Article
Full Access

Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH–cytochrome P450 reductase

Ken-ichi Fujita

Ken-ichi Fujita

Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

Search for more papers by this author
Kazuo Nakayama

Kazuo Nakayama

Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

Search for more papers by this author
Yoshiyuki Yamazaki

Yoshiyuki Yamazaki

Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

Search for more papers by this author
Kazuhiro Tsuruma

Kazuhiro Tsuruma

Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

Search for more papers by this author
Masami Yamada

Masami Yamada

Division of Genetics and Mutagenesis, National Institute of Health Sciences, Tokyo, Japan

Search for more papers by this author
Takehiko Nohmi

Takehiko Nohmi

Division of Genetics and Mutagenesis, National Institute of Health Sciences, Tokyo, Japan

Search for more papers by this author
Tetsuya Kamataki

Corresponding Author

Tetsuya Kamataki

Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita-ku N12W6, Sapporo 060-0812, JapanSearch for more papers by this author
First published: 28 December 2001
Citations: 15

Abstract

A series of Salmonella typhimurium (S. typhimurium) YG7108 strains, each coexpressing a form of human cytochrome P450 (CYP) (CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, or CYP3A5) together with human NADPH–cytochrome P450 reductase (OR), was established. The parental S. typhimurium YG7108, derived from TA1535, lacks two O6-methylguanine-DNA methyltransferase genes, ada and ogt, and is highly sensitive to the mutagenicity of alkylating agents. The expression levels of CYP holo-protein in the genetically engineered S. typhimurium YG7108 cells, determined by carbon monoxide (CO) difference spectra, ranged from 62 nmol/L culture for CYP2C19 to 169 nmol/L culture for CYP3A4. The expression level of the OR varied, depending on the form of CYP coexpressed, and ranged from 214 to 1029 units/L culture. Each form of CYP expressed in the S. typhimurium YG7108 cells catalyzed the oxidation of a representative substrate at an efficient rate. The rates appeared comparable to the reported activities of CYP expressed in human liver microsomes or CYP in other heterologous systems, indicating that the OR was sufficiently expressed to support the catalytic activity of CYP. These S. typhimurium strains may be useful not only for predicting the metabolic activation of promutagens catalyzed by human CYP but also for identifying the CYP form involved. Environ. Mol. Mutagen. 38:329–338, 2001. © 2001 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.